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Poster Session I S209cells/kg. The mean peripheral CD34 count prior to the use of P was
3.3/ul, and increased to 8.8/ul after its use.
Conclusion: Our limited single-center outcomes data suggests that
the addition of P as a salvage agent may improve mobilization out-
comes in poor mobilizers. Further evaluation is needed to combine
P with CY1G in terms of optimal timing and dosing of chemother-
apy utilized.150
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OF CRYOPRESERVATION
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Introduction: Successful transplantation of cryopreserved hemato-
poietic stem cells can be regularly achieved provided sufficient num-
bers of cells are administered. The duration of hematopoietic stem
cell viability is unclear. Evidence of autologous repopulation has
been seen at 14 years after bone marrow transplant and 12 years after
peripheral stem cell transplant. We report a successful autologus
transplantation 21 y after cryopreservation.
Case: The patient is 43 year old man found to have follicular lym-
phoma with bone marrow involvement in 1989 at age 22. He
achieved complete remission after treatment with two cycles of
Chorambucil. Bone marrow (BM) procurement and cryopreserva-
tion was performed at that time for possible subsequent infusion.
The procured BM consisted of a total cell count of 1.21  108
cells/per kg body weight with a total volume of 354 ml. Equal parts
of 20%DMSOwere combined with marrow to a final concentration
of 10% DMSO. The BM was stored in the liquid phase of nitrogen
until date of infusion 21 years later. Our patient relapsed in 1996, and
underwent treatment in 2006 with six cycles of Fludarabine and Rit-
uximab, achieving a complete remission. He continued Rituximab
maintenance and then developped pancytopenia. Work-up con-
firmed MDS with 5q- and t(6q21;17p13) in 20/20 cells by karyotype
analysis. Assessment of previously cryopreserved marrow was under-
taken showing no evidence of cytogenetic or histological changes.
The patient was prepared with Busulfan IV at 0.8/kg q 6 hours 
4 days and Cyclophosphamide 60mg/kg IV  2 days. The BM was
infused and samples from the infused marrow showed 65-75% via-
bility by Tryptan blue assay. White cell engraftment occurred on
day 17 and platelet reached 20,000/uL by day 30.
Follow-up 2months post transplant revealedWBCof 2.6 x103/uL
with ANC 1.5103/uL, Hgb 9.8 gr/dl and platelets of 43,000/uL.
FISH analysis for 5q performed showed 85/200 cells positive for
5q-. BM biopsy confirmed dysplastic features consistent with his
pre-transplant BM.
Our case illustrates that even in the setting of marginal numbers of
infused marrow components and after prolonged cryopreservation,
repopulation can readily occur. To our knowledge, this is the oldest
successful cryopreserved autologous bone transplant at 21 years post
preservation. As novel uses of stem cells advance, optimal storage of
various cellular components is necessary. This should be further
investigated on a larger scale in the future.CLINICAL CELLULAR THERAPY151
TUMOR-INFILTRATING LYMPHOCYTES ARE PRESENT IN CANCER
RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION (ALLOHSCT), OF DONOR ORIGIN, DISTINCT FROM PERIPHERAL
BLOOD DONOR LYMPHOCYTES AND EXHIBIT EFFECTOR FUNCTION
WITH CD3/CD28 COSTIMULATION EX-VIVO
Hardy, N.M., Hakim, F.T., Fellowes, V.S., Rose, J.J., Gress, R.E.,
Bishop, M.R. National Cancer Institute, Bethesda, MD
We theorized that in patients with persistent or relapsed cancer
following alloHSCT, tumor would be a source of tumor-reactivedonor T lymphocytes that could be expanded ex vivo to provide
a potent T cell therapy.We recently reported our initial clinical re-
sults demonstrating feasibility, safety and biologic activity of this
approach in patients with refractory B cell tumor relapse after al-
loHSCT (ASH 2010). We report here the characterization of the
initial tumor infiltrate as compared to circulating T cell popula-
tions, and as compared to expanded products from tumor and
blood. We determined that tumor-infiltrating donor T cells (con-
firmed by chimerism assays) differed from peripheral donor T cell
populations in individual patients in terms of T cell frequency,
na€ıve/memory phenotype, ratio of CD4:CD8 cells and frequencies
of effector and regulatory T cell populations. Following a-CD3/
CD28 antibody-coated bead expansion with low dose IL-2,
PCR-based chimerism assessment of products demonstrated that
the costimulated lymphocytes were of donor origin; by flow, prod-
ucts were greater than 95% CD31 T cells. CD41 T cells usually
predominated, but there was significant patient variation in expan-
sions from both tumor infiltrates and blood. Both expanded tumor
and blood products demonstrated increased expression of markers
of activation and effector function (CD4: CD40L; CD8: CD137,
perforin, NKG2D). The proportion of FoxP31 Treg cells de-
clined and IFN-producing TBet1 Th1/Tc1 effectors became the
dominant T cell population. While the percentage of cells express-
ing CD27 and CD28 declined proportionate to the duration of cul-
ture, their expression was retained in a significant proportion of
cells after our typical 12-day culture. Our findings support the hy-
pothesis that, after allotransplant, donor lymphocytes can be iden-
tified in residual/progressing tumor, and appear to be distinct from
circulating T cell populations. Furthermore, these tumor-infiltrat-
ing T cells can be effectively expanded, even from minor popula-
tions, to become T-Bet1 T effectors, plausibly circumventing
a mechanism of GVL resistance. Costimulated tumor-derived do-
nor lymphocytes may be a therapeutic option for patients without
a source of, or who have not responded to, donor lymphocyte in-
fusion for disease progression after alloHSCT.152
NON-EXPANDED PR1-SPECIFIC CTL SORT-PURIFIED DIRECTLY FROM
CORD BLOOD LYMPHOCYTES DEPLETE HUMAN AML IN VIVO
St. John, L.S., He, H., Quintanilla, K., Ma, Q., Shpall, E.J.,
Alatrash, G., Clise-Dwyer, K., Molldrem, J.J. The University of Texas
M.D. Anderson Cancer Center, Houston, TX
Relapse remains a significant problem following allogeneic stem
cell transplantation (SCT) for AML. Adoptive transfer of leukemia-
specific cytotoxic T lymphocytes (CTL), such as PR1-specific
CTL, might be used to treat persistent leukemia after SCT by en-
hancing graft versus leukemia (GVL) while minimizing graft versus
host disease (GVHD).A limitationof this approach is the limitedper-
sistence of adoptively transferred T cells in the recipient, due in part
to the lengthy ex vivo expansion of low frequency cells necessary to
obtain a sufficient cell number.We chose to study PR1-CTLderived
fromumbilical cord blood (UCB)based onour observation thatUCB
PR1-CTL are increased 100- to 1,000-fold compared to adult pe-
ripheral blood (PB), suggesting UCB might be a rich source of
PR1-CTL. Because UCB is associated with a decreased risk of
GVHD, in part because of the predominance of naive T cells, it
may also be a preferred platform to transfer GVL with minimal risk
of GVHD. We found the frequency of PR1-CTL in UCB to be
0.007 to 0.345% (mean 0.117%; n 5 57) of CD81 cells compared
with a frequency of\0.001% in healthy adult PB. Therefore, we hy-
pothesized that a sufficient number of PR1-CTL fromUCBcould be
obtained by PR1/HLA-A2 tetramer-based cell sorting and infused
without further expansion to mediate GVL. To test this, CD81 T
cells fromHLA-A21UCB units were first enriched via whole blood
negative immunodensity separation. Enriched cells were sorted (.
98% purity) into PR1-CTL and PR1-CTL-depleted CD81 cells
(PDC) and briefly activated ex vivo for 48 hours with soluble anti-
CD3/anti-CD281 IL-2.After 48 hours, PR1-CTLspecifically lysed
PR1-pulsed T2 cells although 95% of PR1-CTL and PDC retained
a CCR71CD45RA1 naive phenotype. Next, 1  104 cells were in-
fused into NOD/SCIDmice engrafted for 7 days with 2-4 106 hu-
man AML blasts. Three separate experiments were performed. Two
